Videos

An expert from Temple reflects on the first 10 years of PrEP innovation, and what's needed in the next decade.

A conversation with Anna Legreid Dopp, Pharm. D.

Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.

What risks and benefits need to be considered with the return of in-person classes?

Contagion Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the quick evolution of this variant and how vaccination rates have influenced this COVID-19 strain.

What are the efforts being made with antibiotic stewardship and treatments, and what areas in clinical care do medical professionals want to see improvements.

A conversation with Anna Legreid Dopp, Pharm. D.

A discussion as to why people with unstable housing living with HIV may not prefer telehealth versus consistent in-person care.

The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.

Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?

Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.

New 24-week findings from Merck highlight the potential of a 1-month PrEP option for low-risk patients.

The Pasteur Act in Congress is designed to incentivize pharmaceutical companies to develop new antibiotics.

Investigators surveyed men who have sex with men (MSM) about long-acting injectable pre-exposure prophylaxis (PrEP) including attitudes towards potentially taking it and barriers to usage.

Perspective gained from persons treated a real-world clinic may help better inform strategies to treat an HIV population that often struggles with viral suppression and consistent care.

As younger generations come of age, there is a continuous need to inform them about HIV risks, offer insights about prevention strategies, and understand the challenges for people living with HIV (PLWH).

A group of personnel at a veterans administration medical center (VAMC)) did a drive-thru to help bolster vaccination amongst coworkers.

The company’s RBX2660, administered as a single dose, demonstrated superiority over standard of care for reducing Clostridioides difficile infection (CDI) recurrence.

In the second installment of an interview, members of the FlowMetric Life Sciences' leadership discuss how their technology might aid possible COVID-19 vaccine booster shots, how immunocompromised patients respond to vaccines, and other vaccines where their platform may be used.

FlowMetric, Inc., discusses its VaxEffect, an immune monitoring platform and how it can be used to measure COVID-19 vaccine responses.

A discussion about the Association for Professionals in Infection Control and Epidemiology with CEO Devin Jopp.

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

COVID-19 response restrained flu outbreaks last year. An expert explains his concern that won't be enough this winter.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

An interview with a study author on unique associations between county infrastructures and COVID-19 fatality rates.

A discussion surrounding Novavax’s NVX-CoV2373 with Lisa Dunkle, MD.

With the company reporting its data today and it applying for authorization with regulatory bodies internationally, and later this year with the US Food and Drug Administration (FDA), what does the prospect of this new vaccine mean to people in the US and internationally?

Cartesian Therapeutics has created its therapy, Descartes-30, the first RNA cell therapy for acute respiratory distress syndrome (ARDS), and the company is now recruiting for a clinical trial.

A Q&A surrounding the two technologies with investigators from the Wistar Institute.